- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02536911
A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
An Open-label Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function
Primary Objective:
To study the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of eliglustat.
Secondary Objective:
To assess the tolerability of eliglustat tartrate given as a single dose in subjects with mild and moderate hepatic impairment in comparison with matched subjects with normal hepatic function.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33014
- Investigational Site Number 840002
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- Investigational Site Number 840001
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria :
For subjects with hepatic impairment:
- Male or female subjects, between 18 and 79 years of age, inclusive.
- Body weight between 50.0 and 125.0 kg, inclusive if male, and between 40.0 and 110.0 kg, inclusive if female, body mass index (BMI) between 18.0 and 37 kg/m^2, inclusive.
- Stable chronic liver disease assessed by medical history, physical examination, laboratory values.
- For moderate hepatic impairment cohort: Child-Pugh total score ranging from 7 to 9, inclusive.
- For mild hepatic impairment cohort: Child-Pugh total score ranging from 5 to 6, inclusive.
For matched subjects:
- Male or female subjects, between 18 and 79 years of age, inclusive.
- Body weight within 15% of the body weight of the subjects with hepatic impairment and BMI between 18.0 and 37 kg/m^2, inclusive.
- Matched by cytochrome P450 (CYP) 2D6 predicted phenotype based on genotype.
- Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
Exclusion criteria:
For subjects with hepatic impairment:
- Uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.
- Hepatocarcinoma.
- Acute hepatitis.
- Hepatic encephalopathy grade 2, 3, and 4.
- Presence or history of drug hypersensitivity, or allergic disease, including active seasonal rhinitis, diagnosed and treated by a physician.
- History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day) within 2 years before inclusion.
- If female, pregnancy (defined as positive beta-human chorionic gonadotropin [β -HCG] blood test), breastfeeding.
- P-gp inhibitors and/or inducers, CYP2D6 and/or CYP3A inhibitors and/or inducers.
- Positive result on any of the following tests: anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti-HIV2 Ab).
- Pre-existing cardiac disease (current congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, ventricular arrhythmia), long QT syndrome, or use of Class IA (eg, quinidine, procainamide) and Class III (eg, amiodarone, sotalol) anti-arrhythmic medications.
- Any subject with CYP2D6 indeterminate or ultra-rapid metabolizer (URM) phenotype.
For matched subjects:
- Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.
- Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician.
- If female, pregnancy (defined as positive β-HCG blood test), breastfeeding.
- For subjects 50 years of age and younger: any medication (including St John's Wort) within 14 days before inclusion, or within 5 times the elimination half-life or pharmacodynamic half-life of that medication, whichever the longest, with the exception of hormonal contraception or menopausal hormone replacement therapy, any vaccination within the last 28 days, and any biologics (antibody or its derivatives) given within 4 months before inclusion.
- For subjects older than 50 years of age: any significant change in chronic treatment medication within 14 days before inclusion.
- P-gp inhibitors and/or inducers, CYP2D6 and/or CYP3A inhibitors and/or inducers.
- Positive result on any of the following tests: hepatitis B surface antigen (HBs Ag), anti-hepatitis C virus (anti-HCV) antibodies, anti-HIV1 and anti-HIV2 Ab.
- History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day) within 2 years before inclusion.
- Pre-existing cardiac disease (current congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, ventricular arrhythmia), long QT syndrome, or use of Class IA (eg, quinidine, procainamide) and Class III (eg, amiodarone, sotalol) anti-arrhythmic medications.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GZ385660 (healthy subjects)
Single dose of eliglustat tartrate will be given under fed conditions
|
Pharmaceutical form: capsule Route of administration: oral
Other Names:
|
Experimental: GZ385660 (subjects with mild hepatic impairment)
Single dose of eliglustat tartrate will be given under fed conditions
|
Pharmaceutical form: capsule Route of administration: oral
Other Names:
|
Experimental: GZ385660 (subjects with moderate hepatic impairment)
Single dose of eliglustat tartrate will be given under fed conditions
|
Pharmaceutical form: capsule Route of administration: oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assessment of PK parameter: Maximum plasma concentration observed (Cmax)
Time Frame: 3 days
|
3 days
|
Assessment of PK parameter: Area under the plasma concentration (AUC)
Time Frame: 3 days
|
3 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assessment of PK parameter: Area under the plasma concentration versus time curve (AUClast)
Time Frame: 3 days
|
3 days
|
Assessment of PK parameter: Apparent total body clearance (CL/F)
Time Frame: 3 days
|
3 days
|
Assessment of PK parameter: Apparent volume of distribution during the terminal phase (Vz/F)
Time Frame: 3 days
|
3 days
|
Assessment of PK parameter: Predicted accumulation ratio (Rac,pred)
Time Frame: 3 days
|
3 days
|
Assessment of PK parameter: Terminal half-life (t1/2z)
Time Frame: 3 days
|
3 days
|
Number of adverse events
Time Frame: Up to 10 days
|
Up to 10 days
|
Change from baseline in ECG parameter
Time Frame: Baseline, Up to 10 days
|
Baseline, Up to 10 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Lipid Metabolism Disorders
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Sphingolipidoses
- Lysosomal Storage Diseases, Nervous System
- Lipidoses
- Lipid Metabolism, Inborn Errors
- Gaucher Disease
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Eliglustat
Other Study ID Numbers
- POP13777
- U1111-1170-3678 (Other Identifier: UTN)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gaucher Disease
-
KemPharm Denmark A/STerminatedGaucher Disease, Type 1 | Gaucher Disease, Type 3India
-
AVROBIOWithdrawn
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited Kingdom, United States
-
Genzyme, a Sanofi CompanyActive, not recruitingGaucher Disease Type 1 | Gaucher Disease Type 3Germany, United States, Japan, United Kingdom
-
Baylor Research InstituteTexas Scottish Rite Hospital for ChildrenWithdrawnGaucher Disease Type 1 | Gaucher Disease Type 3United States
-
CANbridge (Suzhou) Bio-pharma Co., Ltd.RecruitingGaucher Disease, Type 1 | Gaucher Disease, Type 3China
-
Cambridge University Hospitals NHS Foundation TrustMedical Research Council; National Institute for Health Research, United KingdomRecruitingGaucher Disease, Type III | Gaucher Disease, Type IUnited Kingdom
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited States
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited Kingdom, Israel, South Africa, United States
-
Freeline TherapeuticsRecruitingGaucher Disease, Type 1Spain, Israel, United States, United Kingdom, Brazil, Germany, Paraguay
Clinical Trials on eliglustat
-
Genzyme, a Sanofi CompanyCompleted
-
Genzyme, a Sanofi CompanyCompletedGaucher DiseaseCanada, Russian Federation, Tunisia
-
Genzyme, a Sanofi CompanyCompletedGaucher DiseaseUnited States, Sweden, India, Netherlands, Austria, Japan, China, Serbia, France, Croatia, Australia, Portugal, Canada, Brazil, Greece, Romania, Russian Federation
-
SanofiCompletedGaucher DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompleted
-
Genzyme, a Sanofi CompanyCompletedGaucher Disease, Type 1 | Cerebroside Lipidosis Syndrome | Glucocerebrosidase Deficiency Disease | Glucosylceramide Beta-Glucosidase Deficiency Disease | Gaucher Disease, Non-Neuronopathic FormUnited States, Israel, Mexico, Russian Federation, Argentina, Italy
-
SanofiActive, not recruitingGaucher's Disease Type III | Gaucher's Disease Type ICanada, Argentina, France, Italy, Japan, Russian Federation, Spain, Sweden, Turkey, United Kingdom
-
Genzyme, a Sanofi CompanyCompletedGaucher Disease, Type 1United States, United Kingdom, Bulgaria, Canada, Colombia, India, Israel, Lebanon, Mexico, Russian Federation, Serbia, Tunisia
-
Genzyme, a Sanofi CompanyCompletedGaucher Disease, Type 1United States, France, Germany, Italy, Brazil, Australia, Argentina, Canada, Egypt, Russian Federation, Spain, United Kingdom
-
SanofiCompleted